Table 1.
Patient and disease characteristics (N=25)
| Median age, y (range) | 56 (37-65) |
| Sex, N (%) | |
| Male | 14 (56) |
| Female | 11 (44) |
| Durie-Salmon classification, N=24, (%) | |
| Stage Ia | 6 (25) |
| Stage IIa | 7 (29) |
| Stage IIIa | 8 (33) |
| Stage IIIb | 3 (13) |
| International Staging System Classification, N=20, (%) | |
| Stage 1 | 9 (45) |
| Stage 2 | 7 (35) |
| Stage 3 | 4 (20) |
| Immunoglobulin Isotype, N (%) | |
| IgG-κ | 12 (48) |
| IgG-λ | 4 (16) |
| IgA-κ | 3 (12) |
| IgA-λ | 3 (12) |
| Free κ | 2 (8) |
| Free λ | 1 (4) |
| Karnofsky Performance Status prior to ASCT, N (%) | |
| 100 | 6 (24) |
| 90 | 12 (48) |
| 80 | 5 (20) |
| 70 | 1 (4) |
| 60 | 1 (4) |
| Cytogenetic Risk Category, N (%)* | |
| Low Risk | 18 (72) |
| High Risk | 7 (28) |
| Ki67 score, N=22, N (%)** | |
| ≥10% | 7 (32) |
| < 10% | 15 (68) |
| Presence of Extramedullary Disease, N (%) | |
| Yes | 4 (16) |
| No | 21 (84) |
| Lines of Prior Therapy, N (%) | |
| 1 | 19 (76) |
| 2 | 2 (8) |
| 3 | 4 (16) |
| Therapy Exposure History, N (%) | |
| Thalidomide | 5 (20) |
| Lenalidomide | 17 (68) |
| Bortezomib | 16 (64) |
| Alkylating Agent | 6 (24) |
| Liposomal Doxorubicin | 4 (16) |
| Maximum disease response prior to ASCT, N (%) | |
| Progression of disease | 1 (4) |
| Partial response | 6 (24) |
| Very good partial response | 8 (32) |
| Complete response | 5 (20) |
| Stringent complete response | 5 (20) |
*
High risk cytogenetics, [number of patients]: del 13q karyotype, [5]; del 17p, [1]; t(14;16),[1]; amp 1q or del 1p,[4]; complex karyotype, [5].
**
Ki67 score is the ratio of Ki67 positive cells to CD138 cells on immunohistochemical staining of the bone marrow aspirate.